Logo
  • Careers
  • Contact Us
  • Donate
  • Subscribe
Search
  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
      • HIV Vaccine Translational Research Laboratory
      • Human Immunology Laboratory
      • IAVI Neutralizing Antibody Center
      • Vaccine Design and Development Laboratory
    • Translation & Product Development
    • Clinical & Epidemiology Research
      • ADVANCE
      • Clinical Research Centers
      • Clinical Research Standards
      • HIV Epidemiology
    • Global Community Engagement
      • Africa Program
      • CASPR
      • End-User Research
      • World Bank/Japan-supported
        Partnerships | 日本政府・世銀が支援するパートナーシップ
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
  • Careers
  • Contact Us
  • Donate
  • Subscribe

Search

  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
    • Translation & Product Development
    • Clinical & Epidemiology Research
    • Global Community Engagement
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
COVID-19
  • Latest NewsLatest News
  • Scientific Publications Scientific Publications
  • Press Releases
  • Features
  • IAVI Report
  • IAVI in the News
  • Fact Sheets & Publications
  • VOICES Newsletter
  • Media Contacts
  • Subscribe

Scientific Publications

Filter By:

 

 
Filters

Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinsky SM, Zack JAPublic health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004;303(5656):316

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M, Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I, Wolinsky SM, Doms RW, DeMartino JA, Siciliano SJ, Lyons K, Springer MS, Moore JPUse of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 2003;198(10):1551-62

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Human immunodeficiency virus type 1 (HIV-1) fuses with cells after sequential interactions between its envelope glycoproteins, CD4 and a coreceptor, usually CC chemokine receptor 5 (CCR5) or CXC receptor 4 (CXCR4). CMPD 167 is a CCR5-specific small molecule with potent antiviral activity in vitro. We show that CMPD 167 caused a rapid and substantial (4-200-fold) decrease in plasma viremia in six rhesus macaques chronically infected with simian immunodeficiency virus (SIV) strains SIVmac251 or SIVB670, but not in an animal infected with the X4 simian-human immunodeficiency virus (SHIV), SHIV-89.6P. In three of the SIV-infected animals, viremia reduction was sustained. In one, there was a rapid, but partial, rebound and in another, there was a rapid and complete rebound. There was a substantial delay (>21 d) between the end of therapy and the onset of full viremia rebound in two animals. We also evaluated whether vaginal administration of gel-formulated CMPD 167 could prevent vaginal transmission of the R5 virus, SHIV-162P4. Complete protection occurred in only 2 of 11 animals, but early viral replication was significantly less in the 11 CMPD 167-recipients than in 9 controls receiving carrier gel. These findings support the development of small molecule CCR5 inhibitors as antiviral therapies, and possibly as components of a topical microbicide to prevent HIV-1 sexual transmission.

Pierson TC, Doms RWHIV-1 entry and its inhibition. Curr. Top. Microbiol. Immunol. 2003;281:1-27

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Entry of HIV-1 virions into cells is a complex and dynamic process carried out by envelope (Env) glycoproteins on the surface of the virion that promote the thermodynamically unfavorable fusion of highly stable viral and target cell membranes. Insight gained from studies of the mechanism of viral entry allowed insight into the design of novel inhibitors of HIV-1 entry, several of which are now in clinical trials. This review highlights the mechanism by which viral and cellular proteins mediate entry of HIV-1 into permissive cells, with an emphasis on targeting this process in the design of novel therapies that target distinct steps of the entry process, including antagonizing receptor binding events and blocking conformational changes intimately involved in membrane fusion.

Vödrös D, Thorstensson R, Doms RW, Fenyö EM, Reeves JDEvolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. Virology 2003;316(1):17-28

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Coreceptor use of HIV can evolve during infection. We previously examined coreceptor use of related SIVsm inoculum viruses and sequential reisolates from cynomolgus macaques. These viruses exhibited broad coreceptor specificities and, generally, CCR5 use remained efficient and stable, while alternative coreceptor use decreased longitudinally. Here we demonstrate that individual envelopes (Envs) from inoculum and reisolate viruses fuse via a range of coreceptors, including CCR5, CCR8, CXCR6, GPR15, GPR1, and APJ. On the whole, coreceptor use of Envs from sequential reisolates recapitulated that of reisolate viruses, thus CCR5 use remained stable while alternative coreceptor use tended to decrease over time. Rhesus CCR5, GPR15, and CXCR6 supported fusion to a similar extent as their human counterparts. Additionally, a number of Envs mediated CD4-independent fusion via CCR5 and GPR15. Envs from different inoculum viruses exhibited distinct dependencies on CD4 for fusion via CCR5, ranging from strictly CD4-dependent to efficiently CD4-independent. Early reisolates from macaques infected with CD4-independent inoculums maintained or evolved Envs with a broad range of CD4-independence. CD4-independence became less variable/efficient in late reisolates from macaques that developed neutralizing antibodies. Infection with a CD4-dependent virus resulted in evolution of CD4-independent Envs in late reisolates. While CD4 independence can potentially broaden tropism in vivo, CD4-independent viruses are particularly sensitive to neutralizing antibodies. Therefore, interplay between receptor tropism and neutralization may shape viral evolution and SIV pathogenesis.

Otto C, Puffer BA, Pöhlmann S, Doms RW, Kirchhoff FMutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency. Virology 2003;315(2):292-302

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Residues within the highly conserved C3 region of human and simian immunodeficiency virus (HIV, SIV) envelope proteins (Envs) bind directly to the cellular CD4 receptor. However, substitutions of D385, which is critical for CD4 engagement along with other changes such as G382R, G383R, frequently arise in SIV mac-infected macaques. We investigated the influence of substitutions in the SIVmac and HIV-1 C3 regions on viral entry, dependence on CD4, and replication. Mutations flanking the C3 region such as G382R or V388A enhanced and changes within the C3 region (i.e., G383R or D385N) impaired SIVmac infectivity. Several naturally occurring sequence variations in the SIVmac Env C3 region facilitated CD4-independent membrane fusion but abrogated viral replication, suggesting that efficient infection requires additional changes elsewhere in Env. Substitutions of S365R and D368G in the HIV-1 Env, which correspond to G382 and D385 in SIVmac Env, consistently impaired viral infectivity. In contrast, mutation of D368N resulted in a virus that could not spread in cells expressing low levels of CD4, but which replicated efficiently when high levels of CD4 were expressed. Thus, changes in the C3 region of HIV-1 or SIVmac Env can have differential effects on viral infectivity and CD4-dependency. We conclude that substitutions flanking the C3 region in SIVmac Env such as G382R or V388A represent one step toward adaptation to growth in target cells expressing low CD4 levels, whereas changes within the C3 region that disrupt CD4 binding might indicate the emergence of CD4-independent variants at later stages of infection, which could potentially broaden viral tropism.

Xiang SH, Wang L, Abreu M, Huang CC, Kwong PD, Rosenberg E, Robinson JE, Sodroski JEpitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 2003;315(1):124-34

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Human immunodeficiency virus (HIV-1) enters target cells by binding its gp120 exterior envelope glycoprotein to CD4 and one of the chemokine receptors, CCR5 or CXCR4. CD4-induced (CD4i) antibodies bind gp120 more efficiently after CD4 binding and block the interaction with the chemokine receptor. Examples of CD4i antibodies are limited, and the prototypes of the CD4i antibodies exhibit only weak neutralizing activity against primary, clinical HIV-1 isolates. Here we report the identification of a novel antibody, E51, that exhibits CD4-induced binding to gp120 and neutralizes primary HIV-1 more efficiently than the prototypic CD4i antibodies. The E51 antibody blocks the interaction of gp120-CD4 complexes with CCR5 and binds to a highly conserved, basic gp120 element composed of the beta 19-strand and surrounding structures. Thus, on primary HIV-1 isolates, this gp120 region, which has been previously implicated in chemokine receptor binding, is accessible to a subset of CD4i antibodies.

Yang X, Mahony E, Holm GH, Kassa A, Sodroski JRole of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. Virology 2003;313(1):117-25

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

The inner domain of the human immunodeficiency virus (HIV-1) gp120 glycoprotein has been proposed to mediate the noncovalent interaction with the gp41 transmembrane envelope glycoprotein. We used mutagenesis to investigate the functional importance of a conserved beta-sandwich located within the gp120 inner domain. Changes in aliphatic residues lining a hydrophobic groove on the surface of the beta-sandwich decreased the association of the gp120 and gp41 glycoproteins. Other changes in the base of the hydrophobic groove resulted in envelope glycoproteins that were structurally intact and able to bind receptors, but were inefficient in mediating either syncytium formation or virus entry. These results support a model in which the beta-sandwich in the gp120 inner domain contributes to gp120-gp41 contacts, thereby maintaining the integrity of the envelope glycoprotein complex and allowing adjustments in the gp120-gp41 interaction required for membrane fusion.

Karlsson GB, Liljeström PLive viral vectors: Semliki Forest virus. Methods Mol. Med. 2003;87:69-82

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Berkley SThorny issues in the ethics of AIDS vaccine trials. Lancet 2003;362(9388):992

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Moore JP, Doms RWThe entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U.S.A. 2003;100(19):10598-602

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

For HIV-1 to enter a cell, its envelope protein (Env) must sequentially engage CD4 and a chemokine coreceptor, triggering conformational changes in Env that ultimately lead to fusion between the viral and host cell membranes. Each step of the virus entry pathway is a potential target for novel antiviral agents termed entry inhibitors. A growing number of entry inhibitors are under clinical development, with one having already been licensed by the Food and Drug Administration. With the emergence of virus strains that are largely resistant to existing reverse transcriptase and protease inhibitors, the development of entry inhibitors comes at an opportune time. Nonetheless, because all entry inhibitors target in some manner the highly variable Env protein of HIV-1, there are likely to be challenges in their efficient application that are unique to this class of drugs. Env density, receptor expression levels, and differences in affinity and receptor presentation are all factors that could influence the clinical response to this promising class of new antiviral agents.

Page 84 of 87

StartPrev78...8081828384...8687NextEnd

About

About

Board of Directors

Senior Leadership

Financial Statements

Global Funding & Support

Our Work

Our Work

Discovery

Translation & Product Development

Clinical & Epidemiology Research

Global Community Engagement

IAVI DataSpace

Our Science

Our Science

Pipeline

HIV Vaccines

bnAbs for HIV Prevention

Tuberculosis Vaccines

Emerging Infectious Diseases Vaccines and Therapeutics

Snakebite

News & Resources

Latest NewsLatest News

Scientific Publications Scientific Publications

Press Releases

Features

IAVI Report

IAVI in the News

Fact Sheets & Publications

VOICES Newsletter

Media Contacts

Subscribe

icon charity navigator icon guide star icon iavi

Accessibility

Compliance

Contact IAVI

Privacy Policy

Site Map

Supplier Diversity

Terms of Use

©2021 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the International AIDS Vaccine Initiative, Inc.